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There currently are three clinical laboratory procedures for use with cerebrospinal fluid that assist in the diagnosis of multiple sclerosis: measurement of myelin basic protein and lgG, and demonstration of an oligoclonal band. We compared characteristics of these procedures, using CSF samples from 166 patients identified as having (54 patients) or not having (112 patients) multiple sclerosis. We find that oligoclonal band demonstration is the most useful single test in helping to establish the presence of multiple sclerosis; lgG quantitation is the least helpful. Myelin basic protein should be quantitated for following the activity of multiple sclerosis; it may be applied only selectively in the context of screening. The incidence of false-positive results reinforces the view that the diagnosis of multiple sclerosis must be made in clinical context. These laboratory procedures are not suitable for use as screening tests.
AdditIonal Keyphrases: relative value and proper sequence of tests screening other disorders associated with oligoclonal bands in CSF . nervous-system disorders
The diagnosis of multiple sclerosis (MS) rests on clinical observations.
There are objective criteria that if applied uniformly correctly identify this disorder (1, 2) . Unfortunately, no single system of classification is used universally, and modifications may be introduced by clinicians using a single system. 
Procedures
Myelin basic protein qua ntitation. The radioimmunoassay for myelin basic protein has been described in detail (7) .
For the assay, 0.05 mL of a 10-fold concentrated assay buffer (2 mol/L Tris acetate, pH 7.5, containing lOg of histone per liter) and antiserum at the appropriate concentration were added directly to 0.5 mL of spinal fluid. This mixture was incubated for 1 h at 37 #{176}C, 15 000 cpm of 1251-labeled basic protein (specific activity, 10-20 Ci/g) was added, and the mixture was incubated for an additional 18 to 24 hat 4#{176}C. We then precipitated the antibody-basic protein complex by adding 0.5 mL of cold absolute ethanol, and centrifuged. Then we assayed the pellet and supernatant fraction for radioactivity. The percentage of 1251-labeled basic protein bound (i.e., in the pellet) was then calculated (5) . Results were reported as either negative (<4 tg/L), weakly positive (5) (6) (7) (8) or positive (>9 g/L). Oligoclonal bands. CSF was concentrated 80-fold by selective permeability (Minicon CS 15; Arnicon, Lexington, MA 02173).
The high-resolution electrophoresis technique used has been described in detail previously (6) . For each patient, serum and concentrated CSF were electrophoresed on a single agarose gel (Panagel-8; Worthington Diagnostics, Freehold, NJ 07728). Oligoclonal bands were defined as discrete bands in the gamma region of the CSF electrophoretic pattern that were not present in the serum pattern (5 
Data Interpretation
A positive result for each test was: increased myelin basic protein (weakly positive or positive); the presence of oligoclonal bands; IgG greater than or equal to 18% of the total CSF protein (3-9). A negative result for each test was: "normal" level of myelin basic protein; the absence of oligoclonal bands; IgG <18% of the total CSF protein (3) (4) (5) (6) (7) (8) (9) .
We calculated sensitivity, specificity, predictive values, and efficiency (5, 11, 12) . Sensitivity was defined as 100 times the number of MS+ patients who had a positive test, divided by the sum of that number plus the number of MS+ patients who had a negative test (true positives plus false negatives).
Specificity was defined as 100 times the number of MS-patients who had a negative result, divided by the sum of that number plus the number of MS-patients who had a positive test (true negatives plus false positives). The predictive value of a positive test was defined as 100 times the number of MS+ patients who had a positive result, divided by the total number of positive results. The predictive value of a negative test was defined as 100 times the number of MS-patients who had a negative result, divided by the total number of negative results. Efficiency was defined as 100 times the sum of MS+ patients with a positive test result plus MS-patients with a negative test result, divided by the total number of MS+ and MS-patients for whom results were available. Parallel and series combination-testing performance characteristics were used as previously defined (12) .
Results
There were 166 patients included in the study; 54 patients were classified as MS+, 112 patients were classified as MS-. 
Discussion
Myelin basic protein in the CSF of patients considered to have MS is increased during exacerbations of MS and may be within the "normal" range during remission; the value fluctuates with the activity of the disease (3, (7) (8) (9) . Myelin basic protein should be increased even during the very first as well as subsequent episodes of demyelination associated with MS.
The presence of oligoclonal bands sensitively and specifically indicates the presence of demyelinating disease (4-6). The bands may appear within the first year of the clinical course of MS and, once present, they persist in a relatively stable pattern that is unique to the patient (13) . There may be a period of time very early in the course of MS when ohgoclonal bands will not be present in a patient who subsequently will develop them. About 10% of MS+ patients will never show oligoclonal bands in their electrophoretograms.
Increased IgG in the CSF of patients with demyelinating disease is recognized (14, 15) . The overlapping of CSF IgG, expressed as a percentage of total CSF protein, between patients with and without demyelinating diseases is great (5) . The cutoff value used in this study (<18%) is higher than used by most laboratories, but we chose it to enhance specificity for MS at the expense of sensitivity. A lower cutoff would make CSF IgG quantitation a more sensitive screening test at the expense of specificity (more false positives). When used in conjunction with the presence of oligoclonal bands, IgG quantitation dramatically decreases sensitivity while it increases specificity only slightly (5) . IgG does not fluctuate with the activity of MS (3) .
The combination of clinical laboratory procedures ordered in a situation where MS is suspected varies greatly. Clearly, a measurement of CSF IgG alone is least likely to be of value. The myelin basic protein quantitation may be "normal," especially if the patient is at the end of a several-week workup of an episode that is long over. The electrophoretogram may be of little help, especially in a newly presenting case of MS.
This study shows that as an individual clinical laboratory test to help establish the diagnosis of MS, electrophoresis on agarose should be the first choice from among the three procedures studied. Our data are consistent with other reports of 70-90% sensitivity (5, 16) . The addition of myelin basic protein quantitation increases sensitivity and may be appropriate very early in the active disease course (in the proper clinical setting), when the oligoclonal pattern has not been established, or in the 10% of MS+ patients who never will develop an abnormal CSF electrophoresis pattern. The quantitation of IgG expressed as a percentage of total protein in CSF is of limited usefulness as an aid in establishing the presence of MS.
A sequence of tests-the more readily available electrophoresis method being used first, with subsequent quantitation of myelin basic protein on electrophoresis-negative (no oligoclonal bands) samples-is sufficiently powerful to be used as an aid in establishing the diagnosis of MS, but only in the proper clinical context. This sequence decreases the number of occasions necessitating quantitation of myelin basic protein, which frequently entails finding an outside laboratory that does this. Clinical context and judgement remain the fundamental criteria for decision, however. Note that three MSpatients had both increased myelin basic protein and the presence of oligoclonal bands, but the actual diagnoses were cord compression, encephalitis, and metastatic bronchogenic carcinoma. Most clinical laboratories should be able to do and interpret electrophoreses of CSF, but attention must be directed to the relative abilities of systems to demonstrate oligoclonal bands (6) . Also, a serum sample must be submitted with each CSF sample. The simultaneous presence of such bands in both serum and CSF does not have the same significance as the presence of oligoclonal bands only in CSF.
The CSF oligoclonal band pattern and IgG values are stable; they do not fluctuate with the activity of disease. Thus it is inappropriate to request multiple repeat determinations once a positive result has been obtained. Quantitation of myelin basic protein is the appropriate laboratory procedure for following the course of demyelinating disease (3) . It should be the clinical laboratory method for following the course of a patient with an established diagnosis of MS.
Increased concentrations of myelin basic protein indicate the breakdown of myelin and as such are nonspecific for any pathogenesis. The proportion of MS-patients in whose CSF myelin basic protein was increased should not be surprising. Most of these have an assignable cause of breakdown of myelin other than MS (Table 4 ). The presence of oligoclonal bands in the CSF of patients with neurosyphilis, CNS vasculitis, meningitis and (or) encephalitis of several etiologies, subacute sclerosing panencephalitis, progressive rubella panencephalitis, Guillain-Barr#{233} syndrome, and axonal polyneuropathy and granulomatous angitis have been reported (4, 5, (17) (18) (19) . To this list we have added in this study diabetes mellitus, vasculitis (autoimmune), cerebrovascular events (infarct and transient ischemia), and spinal cord compression (Table 4) .
While we present for the first time the results of these three procedures on single samples from patients, caution must be used in extrapolating to clinical situations. Although the patients included in this study were not selected for the presence of suspected demyelinating disease, they were selected in the sense that some disease entity involving the CNS was suspected and prompted submission of CSF to the laboratory. Application of these procedures in an unselected screening fashion is not suggested by our data (11) . The prevalence of MS in the population tested has a profound effect on the performance characteristics of these laboratory procedures. Application of these procedures in the order described above to a properly selected (on the basis of clinical context) population, however, should result in even better performance characteristics than we achieved. Our data are very sensitive to additions or deletions of patients with certain clinical entities that are known to give false-positive results in the context of screening for MS. Clearly, if any of the entities known to be associated withincreased CSF myelin basic protein or the presence of oligoclonal bands or increases in the percentage of IgG is encountered with any frequency (i.e., decreased prevalence of MS), the reliability of these procedures as indicators of MS will be diminished. For this reason it is important to emphasize that establishing the diagnosis of MS is clinical; however, certain laboratory procedures may be of great help when used in the proper clinical context.
